Characterization of recurring EZH2 activating mutations in lymphomas [36] has driven the recent development of several EZH2-specific inhibitors (EZH2i’s: e.g. EPZ6438, GSK126 and UNC1999) which avoid the off-target effects of non-specific histone methyl-transferases inhibitors (i.e. DZNep) previously used to study EZH2 [37–42]. Here, EZH2 is linked to lymphoma.